Interferon‑β and temozolomide combination therapy for temozolomide monotherapy‑refractory malignant gliomas

Kawaji,Hiroshi; Tokuyama,Tsutomu; Yamasaki,Tomohiro; Amano,Shinji; Sakai,Naoto; Namba,Hiroki

doi:10.3892/mco.2015.542

July-2015 Volume 3 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 3 Issue 4

Full Size Image

Article

Interferon‑β and temozolomide combination therapy for temozolomide monotherapy‑refractory malignant gliomas

Authors:
- Hiroshi Kawaji
- Tsutomu Tokuyama
- Tomohiro Yamasaki
- Shinji Amano
- Naoto Sakai
- Hiroki Namba
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431‑3192, Japan
Pages: 909-913
|
Published online on: April 8, 2015

https://doi.org/10.3892/mco.2015.542
Expand metrics +

Abstract

Interferon‑β (IFN‑β) has been found to downregulate O6‑methyl‑guanine‑DNA methyltransferase and sensitize glioma cells to chemoradiation therapy. The effectiveness of IFN‑β and temozolomide (TMZ) combination therapy for newly diagnosed glioblastomas was previously reported. However, there is no clinical report of recurrent of malignant gliomas treated with the combination of IFN‑β and TMZ. In the present study, we reported 7 cases of gliomas classified as uncontrollable with adjuvant TMZ monotherapy, who were then treated with IFN‑β and TMZ combination therapy. The magnetic resonance imaging findings and clinical symptoms improved in the majority of the cases, with tolerable adverse events and minimal residual disability. The overall survival (OS) time from the date of the initial surgery exceeded 13 months, suggesting that this combination therapy was successful in improving the prognosis of malignant gliomas refractory to adjuvant TMZ monotherapy.

View Figures

View References

1	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ohka F, Natsume A and Wakabayashi T: Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012:8784252012. View Article : Google Scholar : PubMed/NCBI
3	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
4	Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65:7573–7579. 2005.PubMed/NCBI
5	Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M and Yoshida J: A combination of IFN-beta and temozolomide in human glioma xenograft models: Implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol. 61:653–659. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wakabayashi T, Kayama T, Nishikawa R, et al: A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): The final report. J Neurooncol. 104:573–577. 2011. View Article : Google Scholar : PubMed/NCBI
7	Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K and Wakabayashi T: Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 117:1721–1730. 2011. View Article : Google Scholar : PubMed/NCBI
8	Fujimaki T, Ishii H, Matsuno A, Arai H and Nakagomi T: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol. 5:892007. View Article : Google Scholar : PubMed/NCBI
9	Park JA, Joe YA, Kim TG and Hong YK: Potentiation of antiglioma effect with combined temozolomide and interferon-β. Oncol Rep. 16:1253–1260. 2006.PubMed/NCBI
10	Felsberg J, Thon N, Eigenbrod S, et al: German Glioma Network: Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 129:659–670. 2011. View Article : Google Scholar : PubMed/NCBI
11	Johannessen TC and Bjerkvig R: Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther. 12:635–642. 2012. View Article : Google Scholar : PubMed/NCBI
12	Saito R, Mizuno M, Hatano M, Kumabe T, Yoshimoto T and Yoshida J: Two different mechanisms of apoptosis resistance observed in interferon-beta induced apoptosis of human glioma cells. J Neurooncol. 67:273–280. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WK and Kang JK: Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res. 6:3354–3360. 2000.PubMed/NCBI
14	Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, Kato T, Chansakul P, Ito M, Kim SU and Wakabayashi T: Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett. 284:71–79. 2009. View Article : Google Scholar : PubMed/NCBI
15	Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G and Weller M: Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther. 13:948–961. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Interferon‑β and temozolomide combination therapy for temozolomide monotherapy‑refractory malignant gliomas

This article is mentioned in:

Abstract

Related Articles